ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
84,230.84
-2.23%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Amneal Pharmaceuticals Inc (AMRX)

  7. Amneal Pharmaceuticals Inc (AMRX) News

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMRX
DateTimeSourceHeadlineSymbolCompany
03/07/20253:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20257:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20256:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20256:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20256:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20256:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20254:02PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/05/20253:57PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
03/04/20255:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
02/28/20255:13AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
02/28/20255:00AMBusiness WireAmneal Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
02/19/20257:00AMBusiness WireAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideNASDAQ:AMRXAmneal Pharmaceuticals Inc
02/05/20253:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
01/29/20257:30AMBusiness WireAmneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025NASDAQ:AMRXAmneal Pharmaceuticals Inc
01/23/20254:49PMEdgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
01/23/20257:00AMBusiness WireAmneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for RifaximinNASDAQ:AMRXAmneal Pharmaceuticals Inc
01/15/20255:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
01/10/20253:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
01/06/20253:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
01/02/20253:48PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
12/04/20247:00AMBusiness WireAmneal to Participate at Upcoming Investor ConferencesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/26/20243:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/25/20243:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/22/20243:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/22/20249:39AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/21/20243:05PMBusiness WireAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/21/20241:01PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/19/20243:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/15/202412:49PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
11/14/20243:11PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMRX

Your Recent History

NYSE
AMC
AMC Entertainment
USOTC
AABB
Asia Broadband (PK)
COIN
XRPUSD
Ripple
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
COOP
Mr Cooper
USOTC
BIEL
Bioelectronics (PK)
USOTC
AFFU
Affluence (PK)
USOTC
RDGL
Vivos (QB)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NASDAQ
LWLG
Lightwave Logic
NASDAQ
TSLA
Tesla
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
NB
NioCorp Developments
USOTC
AZRH
Azure (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads